



OVATION SCIENCE INC. ANNOUNCES PRIVATE PLACEMENT

Vancouver, BC – March 20, 2024 (CSE: OVAT) – Ovation Science Inc. (“Ovation” or the “Company”) announces that it intends to close a private placement for gross proceeds of \$67,500, issuing a total of 1,350,000 Units (as defined below) at a price of \$0.05 per Unit subject to CSE approval (the “Offering”).

Each unit consists of one common share of the Company and one non-transferable share purchase warrant. Each warrant is exercisable to purchase an additional common share at a price of \$0.05 per share for a period of 24 months from closing of the private placement.

The securities issued under the private placement will be subject to a hold period expiring four months and one day from the date of issuance pursuant to applicable Canadian securities laws and relevant restrictions under the securities laws of other jurisdictions where the placees may be residents.

The proceeds of the Offering will be used to advance the business of the company and for general working capital.

About Ovation Science Inc.

Ovation Science is a research and development company that develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed and also distributed under Ovation's own brands; Arlo CBD Beauty and InVibe MD -- all powered by its patented Invisicare skin delivery technology. Invisicare enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over 20 years of pharmaceutical drug delivery experience, Ovation's management and science team have created a unique pipeline of over 30 proprietary medical/wellness topical and transdermal products along with a line of anti-aging/beauty formulas. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, Canada, and Las Vegas, United States.

www.ovationscience.com

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

FOR CORPORATE INQUIRIES:

Doreen McMorran

doreen@ovationscience.com

Phone: 702.588.4646